 Waikato District Health Board		Type: Drug Guideline	Document reference: 6443	Manual Classification: Waikato DHB Drug Guidelines
Title: Nystatin oral liquid for Neonates			Effective date: 14 February 2022	
Facilitator <small>sign/date</small> <i> Kerrie Knox Pharmacist</i>	Authorised <small>sign/date</small> <i> Jutta van den Boom Clinical Director NICU</i>	Authorised <small>sign/date</small> <i> John Barnard Chair Medicines & Therapeutics</i>	Version: 1	Page: 1 of 2
			Document expiry date: 14 February 2025	

© Waikato DHB, February 2022

BRIEF ADMINISTRATION GUIDE

For detailed information refer to The Australasian Neonatal Medicines Formulary [nystatin](#) guideline



Critical Note: there are minor variations between the ANMF and Waikato DHB best practice within this drug guideline – see **yellow shaded text**

- Indications:**
- Prophylaxis in babies with risk factors for systemic candidiasis e.g. use of broad spectrum antibiotics
(refer to NICU guideline Candida Infections and anti-fungal use in the newborn unit)
 - Treatment of oral candidiasis (thrush)
Note: nystatin is not suitable for the treatment of invasive fungal disease

- Route:** Oral, topical to oral mucosa
- Supplied as
- Nystatin oral drops 100,000 units/mL, 24 mL

- Dose:** Prophylaxis of invasive fungal infection
0.25 mL every 6 hours

Treatment of oral candidiasis

1 mL every 6 hours

Note: treatment is usually given for 7 days, and continued for 48 hours after lesions disappear

Preparation and administration

- Shake bottle well before withdrawing the dose
- Administer after a feed (if not NBM)
- Saturate a cotton bud with the required dose and paint on the inside of the mouth

Monitoring

- Observe for improvement or presence of fungal infection

Storage and Stability


- Store nystatin oral drops at room temperature, at or below 25 °C
- Once opened, discard after 7 days

Competency for administration

This procedure is carried out by, or under, the direct supervision of a registered nurse/registered midwife who holds current Waikato DHB Generic Medicine Management.

Associated Documents

- Waikato DHB NICU guideline #1659 [Antibiotic usage in Newborn Unit](#)
- Waikato DHB NICU guideline #6434 Candida Infections and anti-fungal use in the newborn unit

 Waikato District Health Board	Document reference: 6443	Effective date: 14 Feb 2022	Expiry date: 14 Feb 2025	Page: 2 of 2
Title: Nystatin oral liquid for Neonates	Type: Drug Guideline	Version: 1	Authorising initials:	

References

- Australian Neonatal Medicines Formulary. Nystatin Drug Guideline 2021, available from: <https://www.seslhd.health.nsw.gov.au/royal-hospital-for-women/australasian-neonatal-medicines-formulary-anmf>
- New Zealand Formulary for Children (NZFC), version 114, December 2021. Nystatin (oromucosal). Available from: https://www.nzfchildren.org.nz/nzf_6202
- Auckland DHB guideline Nystatin for use in newborn intensive care. 2020. Available from <https://www.starship.org.nz/guidelines/nystatin/>
- Canterbury DHB Neonatal Services. Nystatin Drug Information sheet, available from <https://edu.cdhb.health.nz/Hospitals-Services/Health-Professionals/Neonatal-Clinical-Resources/Neonatal-Drug-Information-Sheets/Documents/Nystatin-236729.pdf>
- Datasheet for Nilstat oral drops. Pharmacy Retailing (NZ) Ltd, May 2019. Accessed via Medsafe <https://www.medsafe.govt.nz/profs/datasheet/n/nilstatcapdrpowdtabcrointvagcr.pdf>

Note: Printed copies are only valid on the day of printing – they are not controlled and may not be the current version in use. Please refer to the online version.

Disclaimer: *This document has been developed by Waikato District Health Board specifically for its own use. Use of this document and any reliance on the information contained therein by any third part is at their own risk and Waikato District Health Board assumes no responsibility whatsoever.*